article thumbnail

Enhancing Patient Care and System Revenue: The Case for Onsite Specialty Pharmacies in 340B Hospitals

Proxsys Rx

According to a report by The American Hospital Association , the number of Americans with chronic medical conditions will grow by a projected 9% between 2020 and 2030, an increase of 14 million people. Moreover, it’s estimated that nearly 90% of all large hospitals are already operating their own specialty pharmacies.

article thumbnail

Enhancing Patient Care and System Revenue: The Case for Onsite Specialty Pharmacies in 340B Hospitals

Proxsys Rx

According to a report by The American Hospital Association , the number of Americans with chronic medical conditions will grow by a projected 9% between 2020 and 2030, an increase of 14 million people. Moreover, it’s estimated that nearly 90% of all large hospitals are already operating their own specialty pharmacies.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Enhancing Patient Care and System Revenue: The Case for Onsite Specialty Pharmacies in 340B Hospitals

Proxsys Rx

According to a report by The American Hospital Association , the number of Americans with chronic medical conditions will grow by a projected 9% between 2020 and 2030, an increase of 14 million people. Moreover, it’s estimated that nearly 90% of all large hospitals are already operating their own specialty pharmacies.

article thumbnail

Top Performing Drug – Trikafta/Kaftrio (May Edition)

PharmaShots

Limited Coverage: Insurance coverage and reimbursement policies may vary, leading to potential barriers for some patients in accessing Trikafta. Threats: Growing competition: Other pharmaceutical companies are developing CFTR modulators and treatments for cystic fibrosis. Terri Laguna M.D.,

article thumbnail

Budget expectation: Bring GST rate on APIs at par with the formulations

Express Pharma

There has been an amendment under income tax provisions to disallow such expenses incurred by pharmaceutical companies in violation of MCI regulations. – For pharma and medical devices policies, the Department of Pharmaceutical is the nodal agency. –

article thumbnail

Drug Manufacturers’ 340B Restrictions Generate New Round Of Media Scrutiny & Criticism

Proxsys Rx

In fact, the report found, 340B DSH hospitals provided $41 billion in uncompensated care in 2020 alone. operating-margin average for 340B DSH hospitals in 2019. operating-margin average for 340B DSH hospitals in 2019. Irrespective of insurance status, no patient pays retail drug prices. drug market. margins vs. 7.7%